[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Stéphanie Baggio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100545160","testing-a-new-method-to-improve-informed-consent-in-prison-research-100545160",false,"NCT06378281","Testing a New Method to Improve Informed Consent in Prison Research","Spark BATIR","Inclusion Criteria:\n\n* inclusion in the parent-RCT\n* age ≥ 18 years\n* good command of French\n* absence of acute psychiatric disorder\n* providing written informed consent for study participation in the parent-RCT\n\nExclusion Criteria:\n\n\\- none.","MALE","18 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Understanding of informed consent is often limited in prison, due to unique challenges faced by detained people. This study will test a modified \"teach-to-goal\" informed consent process compared to standard procedures. Conducted within a larger study on psychiatric outcomes, it aims to enhance ethical practices for vulnerable populations.",[27],"ADHD",[29,30,31],"Informed consent","Prison","Ethics","RECRUITING","2026-03-13",{"date":35,"type":36},"2026-03-17","ACTUAL",{"date":38,"type":36},"2024-05-01",{"date":40,"type":21},"2026-09-30",{"name":42,"class":43},"Stéphanie Baggio","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100503981","phase-3-benefits-of-adhd-treatment-in-detained-people-100503981","NCT05842330","Benefits of ADHD Treatment in Detained People","Benefits of In-prison OROS-methylphenidate vs. Placebo Treatment in Detained People With Attention-deficit\u002FHyperactivity Disorder: A Randomized Controlled Trial","BATIR","Inclusion Criteria:\n\n* age between 18 and 65\n* good command of French\n* stay in prison approx. 4 months at eligibility visit\n* endorsing clinical diagnostic criteria for DSM-5 ADHD\n* providing written informed consent\n\nExclusion Criteria:\n\n* presence of an acute uncontrolled comorbid psychiatric disorder\n* medical contraindication to stimulant prescription\n* potential adverse interaction with another medication\n* already receive ADHD treatment","ALL",{"count":54,"type":21},150,[56],"PHASE3","Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using a randomized controlled trial.",[27],[30,60,61,62],"Health care","Adherence to treatment","Recidivism",{"date":35,"type":36},{"date":65,"type":36},"2024-01-01",{"date":67,"type":21},"2027-10-30",{"name":42,"class":43},1,""]